Brief Report: circRUNX1 as Potential Biomarker for Cancer Recurrence in EGFR Mutation-Positive Surgically Resected NSCLC

Introduction: As recently evidenced by the ADAURA trial, most patients with stages IB to IIIA of resected EGFR-mutant lung adenocarcinoma benefit from osimertinib as adjuvant therapy. Nevertheless, predictive markers of response and recurrence are still an unmet need for more than 10% of these patie...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Carlos Pedraz-Valdunciel, PhD, Masaoki Ito, MD, Stavros Giannoukakos, PhD student, Ana Giménez-Capitán, MSc, Miguel Ángel Molina-Vila, PhD, Rafael Rosell, MD, PhD
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Elsevier 2023-12-01
Σειρά:	JTO Clinical and Research Reports
Θέματα:	CircRUNX1 Biomarker EGFR mutation NSCLC
Διαθέσιμο Online:	http://www.sciencedirect.com/science/article/pii/S2666364323001479
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!